We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

34 hedge funds and large institutions have $6.34M invested in Biotech Acquisition Company Warrant in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

467% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 3

205% more capital invested

Capital invested by funds: $2.08M → $6.34M (+$4.26M)

70% more funds holding

Funds holding: 20 → 34 (+14)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
34
Holders Change
+14
Holders Change %
+70%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
3
Reduced
3
Closed
3
Calls
$1.15M
Puts
–
Net Calls
+$1.15M
Net Calls Change
+$665K

Top Buyers

Rank Fund Capital Flow
1
RA
Ramius Advisors
New York
+$349K
2
LA
Linden Advisors
New York
+$236K
3
PC
Periscope Capital
Ontario, Canada
+$173K
4
DCM
DG Capital Management
New York
+$156K
5
Citadel Advisors
Citadel Advisors
Florida
+$156K

Top Sellers

Rank Fund Capital Flow
1
CCP
Corbin Capital Partners
New York
-$108K
2
MP
Mangrove Partners
Connecticut
-$90K
3
PAMP
Polar Asset Management Partners
Ontario, Canada
-$62.5K
4
WA
Whitebox Advisors
Minnesota
-$43.4K
5
Bank of America
Bank of America
North Carolina
-$41.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.96M +$141K +202,950 New
Citadel Advisors
2
Citadel Advisors
Florida
$578K +$156K +224,996 +50%
RA
3
Ramius Advisors
New York
$432K +$349K +501,826 New
CCP
4
Corbin Capital Partners
New York
$399K -$108K -154,687 -25%
LA
5
Linden Advisors
New York
$294K +$236K +339,424 New
KCM
6
Kingstown Capital Management
New York
$258K +$34.8K +50,000 +20%
ACM
7
Atalaya Capital Management
New York
$239K – – –
Blackstone Inc
8
Blackstone Inc
New York
$215K – – –
PC
9
Periscope Capital
Ontario, Canada
$213K +$173K +248,300 New
DCM
10
DG Capital Management
New York
$193K +$156K +224,999 New
PAMP
11
Polar Asset Management Partners
Ontario, Canada
$181K -$62.5K -89,900 -30%
Nomura Holdings
12
Nomura Holdings
Japan
$161K +$139K +200,000 New
KSCM
13
Kamunting Street Capital Management
Florida
$137K +$110K +158,962 New
SC
14
Sculptor Capital
New York
$130K – – –
FTCM
15
Fir Tree Capital Management
New York
$129K – – –
DKCM
16
Davidson Kempner Capital Management
New York
$129K +$104K +150,000 New
TCM
17
Tenor Capital Management
New York
$121K – – –
CH
18
CVI Holdings
Delaware
$86K – – –
PSAMP
19
P. Schoenfeld Asset Management (PSAM)
New York
$86K +$69.5K +100,000 New
TI
20
Telemetry Investments
New York
$73K +$59.1K +85,000 New
WAM
21
Wolverine Asset Management
Illinois
$54K +$44.3K +63,796 New
Jane Street
22
Jane Street
New York
$44K +$617 +887 +2%
CCA
23
Castle Creek Arbitrage
Colorado
$43K – – –
CP
24
Centerbridge Partners
New York
$43K – – –
LP
25
LMR Partners
United Kingdom
$43K +$34.8K +50,000 New
1
2

BIOTW Hedge Fund Activity: Q2 2021 in Review

34 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q2 2021, worth a combined $6.34M — up 205% from $2.08M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BIOTW positions and 3 closed out — a net gain of 14 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Ramius Advisors, opening a new position worth an estimated $349K. The largest seller was Corbin Capital Partners, cutting an estimated $108K.

  • 34 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q2 2021, up from 20 in Q1 2021.
  • Funds reported $6.34M of Biotech Acquisition Company Warrant stock for Q2 2021, up 205% quarter-over-quarter.
  • 17 funds opened new Biotech Acquisition Company Warrant positions in Q2 2021 and 3 closed out, a net change of +14 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q2 2021 was Ramius Advisors, an estimated $349K added.
  • The largest Biotech Acquisition Company Warrant seller in Q2 2021 was Corbin Capital Partners, an estimated $108K sold.

Based on aggregated 13F filings for Q2 2021.